{"title":"Program in Detail","authors":"","doi":"10.1111/ajco.70189","DOIUrl":"https://doi.org/10.1111/ajco.70189","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 S5","pages":"31-49"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149311369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ming Tang, Kaitai Liu, Zhuo Wu, Yihui Yang, Zhoushu Zheng, Changzeng Zhou, Yongbo Zhang, Xiaoyan Li
{"title":"Divergent Trends in Head and Neck Cancer Burden in China (1990-2021).","authors":"Ming Tang, Kaitai Liu, Zhuo Wu, Yihui Yang, Zhoushu Zheng, Changzeng Zhou, Yongbo Zhang, Xiaoyan Li","doi":"10.1111/ajco.70161","DOIUrl":"https://doi.org/10.1111/ajco.70161","url":null,"abstract":"<p><strong>Introduction: </strong>To systematically quantify China's head and neck cancer burden (1990-2021) and inform prevention strategies through analysis of nasopharyngeal carcinoma (NPC), esophageal cancer, and oral cancer trends.</p><p><strong>Methods: </strong>Data were sourced from the Global Burden of Disease Study 2021. Age-standardized incidence rate (ASIR), mortality, and disability-adjusted life year (DALY) rates were analyzed. Temporal trends were evaluated using estimated annual percentage changes (EAPC).</p><p><strong>Results: </strong>During 1990-2021, China observed an overall burden reduction for NPC and esophageal cancer, whereas oral cancer demonstrated rising ASIR (EAPC = 1.75) despite slight declines in mortality and DALY rates, likely reflecting improved survival from earlier detection and advances in treatment. Esophageal cancer showed significant decreases in both ASIR (EAPC = -1.88) and DALY rate (EAPC = -2.67). Gender disparities revealed consistently higher male burdens across all three cancers, though females experienced steeper declines; oral cancer showed divergent trends with substantial male ASIR growth (EAPC = 2.39) versus female improvements. Regarding age distribution, the incidence of NPC and esophageal carcinoma declined among children, young adults, and middle-aged individuals but escalated in elderly men. The incidence of oral cancer increased notably with age.</p><p><strong>Conclusion: </strong>Declining NPC and esophageal cancer burdens contrasted with increasing oral cancer ASIR in China (1990-2021). While males carried disproportionately higher burdens, females exhibited more rapid improvements. The sharply escalating cancer incidence among elderly males underscores critical needs for targeted interventions in high-risk demographics alongside sustained prevention efforts for younger populations.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cancer of Unknown Primary in Transition: From Empirical Chemotherapy to Immunotherapy and Molecularly Guided Treatment.","authors":"Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa","doi":"10.1111/ajco.70220","DOIUrl":"https://doi.org/10.1111/ajco.70220","url":null,"abstract":"<p><p>Cancer of unknown primary (CUP) is a heterogeneous group of metastatic malignancies in which the primary site remains unidentified despite appropriate diagnostic evaluation. Historically, most patients with unfavorable CUP have received empirical platinum-based chemotherapy, but recent advances in immune checkpoint inhibition, comprehensive genomic profiling (CGP), tissue-agnostic therapy, and tissue-of-origin prediction are changing the treatment landscape. Contemporary management therefore requires integration rather than simple replacement of empirical therapy. Randomized evidence from CUPISCO supports early CGP with subsequent molecularly guided treatment after disease control with platinum-based induction, while CUP-specific immunotherapy studies and Japanese real-world data demonstrate clinically meaningful activity in selected patients. Conversely, randomized tissue-of-origin-directed trials have produced mixed results, underscoring the need to distinguish diagnostic prediction from proven therapeutic benefit. Major guidelines broadly agree on purposeful diagnostic evaluation, recognition of favorable subsets, and individualized management, but differ in the timing and emphasis placed on molecular testing and tissue-of-origin assays. These differences are particularly relevant in the Asia-Pacific region, where access, reimbursement, turnaround time, and treatment availability vary substantially. This narrative review synthesizes contemporary evidence and proposes a practical four-layer algorithm in which clinical urgency, tissue and biomarker readiness, and precision opportunities are assessed in parallel. The central principle is that clinically indicated therapy should not be delayed solely while awaiting molecular results; instead, empirical treatment and biomarker planning should be coordinated to preserve treatment opportunities.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aaron K Wong, Helen McManus, Sara Vogrin, Youseph Dib, Monnette Samo, Jonathan La, Brian Le, Jennifer Philip
{"title":"Opioid Prescribing Changes in Advanced Cancer Before and After Withdrawal of Hydromorphone Slow-Release Tablets.","authors":"Aaron K Wong, Helen McManus, Sara Vogrin, Youseph Dib, Monnette Samo, Jonathan La, Brian Le, Jennifer Philip","doi":"10.1111/ajco.70216","DOIUrl":"https://doi.org/10.1111/ajco.70216","url":null,"abstract":"<p><strong>Aim: </strong>Ongoing disruptions to opioid supply in Australia have raised ongoing concerns about their impact on cancer pain management. The withdrawal of hydromorphone slow-release (SR) tablets from the Australian market has presented challenges to advanced cancer pain management. This study aimed to determine how this affected the utilisation of alternative slow-release opioids in patients with advanced cancer.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at a quaternary cancer centre, comparing opioid prescribing patterns across two 12-month periods: before hydromorphone SR tablet discontinuation was announced and after its discontinuation. Inpatient and outpatient prescribing data were analysed for adult patients with incurable advanced or metastatic cancer who first presented to the centre during each study period.</p><p><strong>Results: </strong>A total of 2856 patients were included (n = 1475 pre and n = 1381 post hydromorphone SR discontinuation). Following hydromorphone SR withdrawal, opioid prescribing patterns shifted. Methadone use rose modestly (adjusted odds ratio [aOR] 1.42, p = 0.07), accompanied by a doubling of median dose (45 mg vs. 22.5 mg; p = 0.005). Morphine use declined (aOR 0.69, p < 0.001), yet daily OMEDD increased by ∼20% (95% confidence interval 1.01-1.37). Tapentadol (aOR 1.40, p = 0.01) and buprenorphine (aOR 1.37, p < 0.001) were prescribed more frequently, without corresponding dose escalation.</p><p><strong>Conclusions: </strong>Following hydromorphone SR withdrawal, the frequency of methadone use increased and median doses doubled. Research incorporating national datasets is needed to clarify the broader impact of opioid supply interruptions. These findings indicate a potential need to reframe the place of methadone in practice, and potentially upscale the focus of clinician training on its safe and effective use.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Re: \"Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer.\"","authors":"Gharbi Lassad","doi":"10.1111/ajco.70219","DOIUrl":"https://doi.org/10.1111/ajco.70219","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Importance of Driver-Targeted Therapy Among Patients With Lung Cancer Initially Diagnosed in the Intensive Care Unit","authors":"Yi-Chun Hsiao, Wei-Fan Ou, Po-Hsin Lee, Yu-Wei Hsu, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang","doi":"10.1111/ajco.70149","DOIUrl":"10.1111/ajco.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients who had been diagnosed with lung cancer during intensive care unit (ICU) admission showed poor prognosis. This research investigated the clinical characteristics related to the outcomes of these patients and focused on the potential benefit of driver-targeted therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From February 2011 to October 2022, we included patients who were initially diagnosed with lung cancer during ICU admission in Taichung Veterans General Hospital. We evaluated their clinicopathological factors, overall survival, and hospital discharge outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included a total of 57 patients. The most frequent reasons for ICU entry were central nervous system metastasis (36.8%), respiratory tract infections (26.3%), and tumor with main airway compression (15.8%). The median APACHE II score was 23 (range: 6–40). Bronchoscopy (47.4%) followed by brain craniotomy (22.8%) were the most common biopsy methods, while adenocarcinoma (68.4%) accounted for the most common histology. Eighteen patients received driver-targeted therapy. Tumor as the primary reason for ICU admission (aOR 4.90 [95% CI 1.22–19.6], <i>p = </i>0.025) and driver-targeted therapy (aOR 2.80 [95% CI 1.01–7.69], <i>p = </i>0.048) both independently predicted a higher chance of ventilator-independent hospital discharge. Significant factors for a longer overall survival included tumor as the primary reason for ICU admission (aHR 0.63 [95% CI 0.40–0.99], <i>p = </i>0.046), a lower baseline APACHE II score (aHR 0.62 [95% CI 0.40–0.96], <i>p = </i>0.031), and driver-targeted therapy (aHR 0.17 [95% CI 0.05–0.51], <i>p = </i>0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Driver-targeted therapy was associated with a favorable hospital discharge outcome and a longer overall survival. Performing a biopsy to confirm diagnosis and oncogenic driver(s) testing are recommended.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"844-852"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}